News and Trends 13 Nov 2017
Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma
Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […]